Skip to main content
Premium Trial:

Request an Annual Quote

Galileo Genomics Raises $9M in Venture Capital, Changes Name

NEW YORK, Dec. 13 (GenomeWeb News) - Galileo Genomics has raised CAN$11.1 million ($9 million) in the second tranche of a Series B financing round, the company said today.

 

The company also announced today that it has changed its name to Genizon BioSciences in order to reflect its recently expanded scope.

 

New investors involved in the financing include Solidarity Fund, which acted as the lead for the round. Existing investors taking part in the Series B financing included HBM BioVentures, MVI, Biofund, and Carnegie, Galileo said.

 

"Over the past year, we have demonstrated that our proprietary genetic approach results in the discovery of multiple key disease-genes in common diseases," John Hooper, president and CEO of Genizon, said in a statement. "We have also expanded our capabilities to include downstream pathway analysis and target identification. ... Our new name reflects this evolution."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.